Advertisement

Breast Cancer Research and Treatment

, Volume 171, Issue 3, pp 649–656 | Cite as

Prediction of ovarian function recovery in young breast cancer patients after protection with gonadotropin-releasing hormone agonist during chemotherapy

  • Dong-Yun Lee
  • Yeon Hee Park
  • Jeong Eon Lee
  • DooSeok ChoiEmail author
Clinical trial

Abstract

Purpose

This study evaluated predictive factors for recovery of ovarian function after ovarian protection by GnRH agonist during chemotherapy in young breast cancer patients.

Methods

This prospective cohort study analyzed 105 young breast cancer patients who were studied longitudinally after receiving GnRH agonist during cyclophosphamide-based chemotherapy for ovarian protection. Associations between pretreatment hormones, clinical factors, and recovery of ovarian function (resumption of menstruation or anti-Müllerian hormone (AMH) ≥ 1 ng/ml) were evaluated at 12 months and long-term follow-up after completion of chemotherapy.

Results

Mean age was 32 years (range 23–42 years). In multivariate analyses, tamoxifen use (P = 0.035) and pretreatment follicle-stimulating hormone (FSH) (P = 0.032) were predictive of resumption of menstruation, and age (P = 0.019), tamoxifen use (P = 0.022), pretreatment FSH (P < 0.001), and AMH (P = 0.040) were predictors for AMH ≥ 1 ng/ml at 12 months. In addition, pretreatment AMH was a predictor for AMH ≥ 1 ng/ml after long-term follow-up. Receiver operating characteristic curve analyses gave area under the curve of 0.805 for resumption of menstruation and 0.903 for serum AMH concentration ≥ 1 ng/ml at 12 months, when age, tamoxifen use, pretreatment FSH, and AMH were combined.

Conclusion

Pretreatment AMH (3.26 ng/ml), age (33.9 years), pretreatment FSH (5.5 IU/l), and tamoxifen use are useful predictors for AMH ≥ 1 ng/ml at 12 months after GnRH agonist. This finding will support patient and clinician decision-making regarding fertility preservation.

Keywords

Breast cancer Chemotherapy Ovarian protection Gonadotropin-releasing hormone agonist 

Notes

Acknowledgements

The authors wish to gratefully acknowledge the biostatistics team of Samsung Biomedical Research Institute, Seoul, Korea for assistance in the preparation of this article.

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

References

  1. 1.
    Peto R et al (2012) Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials. Lancet 379(9814):432–444CrossRefPubMedGoogle Scholar
  2. 2.
    Loren AW et al (2013) Fertility preservation for patients with cancer: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol 31(19):2500–2510CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Anders CK et al (2008) Young age at diagnosis correlates with worse prognosis and defines a subset of breast cancers with shared patterns of gene expression. J Clin Oncol 26(20):3324–3330CrossRefPubMedGoogle Scholar
  4. 4.
    Thomas-Teinturier C et al (2015) Ovarian reserve after treatment with alkylating agents during childhood. Hum Reprod 30(6):1437–1446CrossRefPubMedGoogle Scholar
  5. 5.
    Lee SJ et al (2006) American Society of Clinical Oncology recommendations on fertility preservation in cancer patients. J Clin Oncol 24(18):2917–2931CrossRefPubMedGoogle Scholar
  6. 6.
    Practice Committee of American Society for Reproductive Medicine (2013) Fertility preservation in patients undergoing gonadotoxic therapy or gonadectomy: a committee opinion. Fertil Steril 100(5):1214–1223CrossRefGoogle Scholar
  7. 7.
    Del Mastro L et al (2011) Effect of the gonadotropin-releasing hormone analogue triptorelin on the occurrence of chemotherapy-induced early menopause in premenopausal women with breast cancer: a randomized trial. JAMA 306(3):269–276PubMedGoogle Scholar
  8. 8.
    Del Mastro L et al (2014) Gonadotropin-releasing hormone analogues for the prevention of chemotherapy-induced premature ovarian failure in cancer women: systematic review and meta-analysis of randomized trials. Cancer Treat Rev 40(5):675–683CrossRefPubMedGoogle Scholar
  9. 9.
    Blumenfeld Z, Zur H, Dann EJ (2015) Gonadotropin-Releasing Hormone Agonist Cotreatment During Chemotherapy May Increase Pregnancy Rate in Survivors. Oncologist 20(11):1283–1289CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Coates AS et al (2015) Tailoring therapies–improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015. Ann Oncol 26(8):1533–1546CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Moore HC et al (2015) Goserelin for ovarian protection during breast-cancer adjuvant chemotherapy. N Engl J Med 372(10):923–932CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Lambertini M et al (2016) Cancer and fertility preservation: international recommendations from an expert meeting. BMC Med 14:1CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Leonard RCF et al (2017) GnRH agonist for protection against ovarian toxicity during chemotherapy for early breast cancer: the Anglo Celtic Group OPTION trial. Ann Oncol 28(8):1811–1816CrossRefPubMedGoogle Scholar
  14. 14.
    Nelson SM et al (2007) Serum anti-Müllerian hormone and FSH: prediction of live birth and extremes of response in stimulated cycles—implications for individualization of therapy. Hum Reprod 22(9):2414–2421CrossRefPubMedGoogle Scholar
  15. 15.
    Lambertini M et al (2015) Ovarian suppression using luteinizing hormone-releasing hormone agonists during chemotherapy to preserve ovarian function and fertility of breast cancer patients: a meta-analysis of randomized studies. Ann Oncol 26(12):2408–2419PubMedGoogle Scholar
  16. 16.
    Badawy A, Elnashar A, El-Ashry M, Shahat M (2009) Gonadotropin-releasing hormone agonists for prevention of chemotherapy-induced ovarian damage: prospective randomized study. Fertil Steril 91(3):694–697CrossRefPubMedGoogle Scholar
  17. 17.
    Song G, Gao H, Yuan Z (2013) Effect of leuprolide acetate on ovarian function after cyclophosphamide-doxorubicin-based chemotherapy in premenopausal patients with breast cancer: results from a phase II randomized trial. Med Oncol 30(3):667CrossRefPubMedGoogle Scholar
  18. 18.
    Henry NL et al (2014) Prediction of postchemotherapy ovarian function using markers of ovarian reserve. Oncologist 19(1):68–74CrossRefPubMedGoogle Scholar
  19. 19.
    Anderson RA, Rosendahl M, Kelsey TW, Cameron DA (2013) Pretreatment anti-Mullerian hormone predicts for loss of ovarian function after chemotherapy for early breast cancer. Eur J Cancer 49(16):3404–3411CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Anderson RA et al (2006) The effects of chemotherapy and long-term gonadotrophin suppression on the ovarian reserve in premenopausal women with breast cancer. Hum Reprod 21(10):2583–2592CrossRefPubMedGoogle Scholar
  21. 21.
    Anders C et al (2008) A pilot study of predictive markers of chemotherapy-related amenorrhea among premenopausal women with early stage breast cancer. Cancer Invest 26(3):286–295CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Pagani O et al (1998) Prognostic impact of amenorrhoea after adjuvant chemotherapy in premenopausal breast cancer patients with axillary node involvement: results of the International Breast Cancer Study Group (IBCSG) Trial VI. Eur J Cancer 34(5):632–640CrossRefPubMedGoogle Scholar
  23. 23.
    Jeruss JS, Woodruff TK (2009) Preservation of fertility in patients with cancer. N Engl J Med 360(9):902–911CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    Swain SM et al (2009) Amenorrhea in premenopausal women on the doxorubicin-and-cyclophosphamide-followed-by-docetaxel arm of NSABP B-30 trial. Breast Cancer Res Treat 113(2):315–320CrossRefPubMedGoogle Scholar
  25. 25.
    Anderson RA, Cameron DA (2011) Pretreatment serum anti-Mullerian hormone predicts long-term ovarian function and bone mass after chemotherapy for early breast cancer. J Clin Endocrinol Metab 96(5):1336–1343CrossRefPubMedGoogle Scholar
  26. 26.
    Ruddy KJ et al (2014) Biomarker prediction of chemotherapy-related amenorrhea in premenopausal women with breast cancer participating in E5103. Breast Cancer Res Treat 144(3):591–597CrossRefPubMedPubMedCentralGoogle Scholar
  27. 27.
    Partridge AH et al (2010) Ovarian reserve in women who remain premenopausal after chemotherapy for early stage breast cancer. Fertil Steril 94(2):638–644CrossRefPubMedGoogle Scholar
  28. 28.
    Yu B et al (2010) Changes in markers of ovarian reserve and endocrine function in young women with breast cancer undergoing adjuvant chemotherapy. Cancer 116(9):2099–2105PubMedPubMedCentralGoogle Scholar
  29. 29.
    Han HS et al (2009) Analysis of chemotherapy-induced amenorrhea rates by three different anthracycline and taxane containing regimens for early breast cancer. Breast Cancer Res Treat 115(2):335–342CrossRefPubMedGoogle Scholar
  30. 30.
    Petrek JA et al (2006) Incidence, time course, and determinants of menstrual bleeding after breast cancer treatment: a prospective study. J Clin Oncol 24(7):1045–1051CrossRefPubMedGoogle Scholar
  31. 31.
    Anderson RA et al (2017) The utility of anti-Müllerian hormone in the diagnosis and prediction of loss of ovarian function following chemotherapy for early breast cancer. Eur J Cancer 87:58–64CrossRefPubMedPubMedCentralGoogle Scholar
  32. 32.
    Dezellus A et al (2017) Prospective evaluation of serum anti-Müllerian hormone dynamics in 250 women of reproductive age treated with chemotherapy for breast cancer. Eur J Cancer 79:72–80CrossRefPubMedGoogle Scholar
  33. 33.
    Shandley LM et al (2017) Impact of tamoxifen therapy on fertility in breast cancer survivors. Fertil Steril 107(1):243.e5–252.e5CrossRefGoogle Scholar
  34. 34.
    Arriagada R et al (2005) Randomized trial of adjuvant ovarian suppression in 926 premenopausal patients with early breast cancer treated with adjuvant chemotherapy. Ann Oncol 16(3):389–396CrossRefPubMedGoogle Scholar
  35. 35.
    Pagani O et al (2014) Adjuvant exemestane with ovarian suppression in premenopausal breast cancer. N Engl J Med 371(2):107–118CrossRefPubMedPubMedCentralGoogle Scholar
  36. 36.
    Lambertini M et al (2015) Ovarian suppression with triptorelin during adjuvant breast cancer chemotherapy and long-term ovarian function, pregnancies, and disease-free survival: a randomized clinical trial. JAMA 314(24):2632–2640CrossRefPubMedGoogle Scholar
  37. 37.
    Larsen EC et al (2003) Reduced ovarian function in long-term survivors of radiation- and chemotherapy-treated childhood cancer. J Clin Endocrinol Metab 88(11):5307–5314CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Department of Obstetrics and Gynecology, Samsung Medical CenterSungkyunkwan University School of MedicineSeoulRepublic of Korea
  2. 2.Department of Medicine, Samsung Medical CenterSungkyunkwan University School of MedicineSeoulRepublic of Korea
  3. 3.Department of Surgery, Samsung Medical CenterSungkyunkwan University School of MedicineSeoulRepublic of Korea

Personalised recommendations